08:30 AM EST, 12/02/2024 (MT Newswires) -- Esperion Therapeutics ( ESPR ) said Monday it has submitted New Drug Submissions to Health Canada for Nexletol and Nexlizet, oral non-statin medications designed to lower LDL cholesterol and potentially reduce cardiovascular risks in patients unable to tolerate statins.

The company said the medications are intended for adults with established cardiovascular disease or those at high risk of a cardiovascular event.